LETTER   Open Access    

Basiliximab is the potential solution for severe liver chronic GVHD: A prospective pilot study

More Information
  • Corresponding author: moxiaodong@bjmu.edu.cn
  • 加载中
  • [1] Mo, X.D., Zhang, X.H., Xu, L.P., et al. (2021). Disease risk comorbidity index for patients receiving haploidentical allogeneic hematopoietic transplantation. Engineering. 7, 162−922.

    View in Article CrossRef Google Scholar

    [2] Lv, M., Shen, M.Z., Mo, X.D. (2023). Development of allogeneic hematopoietic stem cell transplantation in 2022: Regenerating “Groot” to heal the world. The Innovation. 4, 10037311.

    View in Article Google Scholar

    [3] Mo, X.D., Xu, L.P., Liu, D.H., et al. (2013). Health related quality of life among patients with chronic graft-versus-host disease in China. Chinese Medical Journal. 126, 3048−3052.

    View in Article Google Scholar

    [4] Fan, S., Huo, W.X., Yang, Y., et al. (2022). Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis. Frontiers in immunology. 13, 954268.

    View in Article CrossRef Google Scholar

    [5] Shen, M.Z., Li, J.X., Zhang, X.H., et al. (2021). Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease. Frontiers in immunology. 12, 749266.

    View in Article CrossRef Google Scholar

    [6] Mo, X.D., Hong, S.D., Zhao, Y.L., et al. (2022). Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis. American journal of hematology. 97, 458−469.

    View in Article CrossRef Google Scholar

    [7] Shen, M.Z., Hong, S.D., Lou, R., et al. (2022). A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation. Experimental hematology & oncology. 11, 25.

    View in Article Google Scholar

    [8] Duarte, R.F., Delgado, J., Shaw, B.E., et al. (2005). Histologic features of the liver biopsy predict the clinical outcome for patients with graft-versus-host disease of the liver. Biology of blood and marrow transplantation. 11, 805−813.

    View in Article CrossRef Google Scholar

    [9] Shen, M.Z., Zhang, X.H., Xu, L.P., et al. (2022). Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies. Frontiers in immunology. 13, 757002.

    View in Article CrossRef Google Scholar

    [10] Liu, S.N., Zhang, X.H., Xu, L.P., et al. (2020). Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study. American journal of hematology. 95, 927−936.

    View in Article CrossRef Google Scholar

  • Cite this article:

    Deng D., Shen M., Zhang X., et al., (2023). Basiliximab is the potential solution for severe liver chronic GVHD: A prospective pilot study. The Innovation Medicine 1(1), 100009. https://doi.org/10.59717/j.xinn-med.2023.100009
    Deng D., Shen M., Zhang X., et al., (2023). Basiliximab is the potential solution for severe liver chronic GVHD: A prospective pilot study. The Innovation Medicine 1(1), 100009. https://doi.org/10.59717/j.xinn-med.2023.100009

Figures(1)     Tables(1)

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(1881) PDF downloads(358) Cited by(0)

Relative Articles

Article Contents

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint